Journal
NANO TODAY
Volume 17, Issue -, Pages 23-37Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.nantod.2017.10.008
Keywords
Cancer immunotherapy; Nanoparticles; Targeted delivery; Drug delivery system; Vaccines; Tumor immune evasion; Exosome
Categories
Funding
- National Research Foundation of Korea (NRF) - Korea government [2017R1A2B2010292]
- KU-KIST Graduate School of Conversing Science and Technology Program
- MIST institutional Program
- National Research Foundation of Korea [2017R1A2B2010292] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Although cancer immunotherapy, represented by chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint-blockade therapies, has shown durable outcomes, the percentage of patients that respond to these approaches remains modest to date. However, encouraging recent advances suggest that nanotechnology has the potential to enhance the efficacy of such immunotherapies by improving the delivery, biodistribution, and release-kinetics of immunostimulatory small molecules and biologics in targeted tissues. A variety of synthetic nanoparticles, including polymeric nanoparticles, liposomes and inorganic nanoparticles, can be engineered according to their intended uses in cancer immunotherapy. Notably, nature-derived nanoparticles have emerged as a new class of immunotherapeutics. In this review, we describe state-of-the-art strategies for cancer immunotherapy using designed nanoparticles. We also highlight key translational challenges and opportunities in this rapidly growing field. (C) 2017 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available